Payment overview · 2025
General Payments
$1,108.45
54 reported records · 26 companies
Healthcare provider profile · identity verified
Cheng Xin Jiang
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1174043301
Verified facts
What the public records show
CMS Open Payments records show Cheng Xin Jiang received $1,108.45 in general payments during 2025 across 54 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Farxiga, Jardiance, Linzess, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.03 | 18.8% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $114.01 | 10.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.48 | 7.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.33 | 7.7% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.90 | 5.4% | 3 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.76 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.83 | 4.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.26 | 4.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.09 | 3.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.40 | 3.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.96 | 3.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.19 | 2.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $25.02 | 2.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.06 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.20 | 2.0% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $21.65 | 1.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.43 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.82 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.79 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.68 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.18 | 1.6% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.36 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.12 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.74 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.33 | 1.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.83 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,108.45 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $114.01 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $99.79 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.12 | 3 | 2025 |
Source payment records
|
|||||
| Trelstar Normalized: trelstar |
Drug | Verity Pharmaceuticals Inc. | $54.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.26 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.38 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.92 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 23 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 41 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 113 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 740 | 210 |
| Losartan Potassium | Losartan Potassium | 444 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 99 |
| Gabapentin | Gabapentin | 321 | 89 |
| Omeprazole | Omeprazole | 262 | 73 |
| Lisinopril | Lisinopril | 254 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 213 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 52 |
| Alprazolam | Alprazolam | 188 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 63 |
| Trazodone Hcl | Trazodone Hcl | 172 | 56 |
| Tramadol Hcl | Tramadol Hcl | 170 | 61 |
| Sertraline Hcl | Sertraline Hcl | 158 | 45 |
| Metformin Hcl | Metformin Hcl | 155 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 42 |
| Metformin Hcl Er | Metformin Hcl | 133 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 39 |
| Alendronate Sodium | Alendronate Sodium | 127 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 31 |
| Eliquis | Apixaban | 113 | 20 |
| Furosemide | Furosemide | 102 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 22 |
| Meloxicam | Meloxicam | 93 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 23 |
| Jardiance | Empagliflozin | 90 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 26 |
| Celecoxib | Celecoxib | 80 | 24 |
| Potassium Chloride | Potassium Chloride | 80 | 22 |
| Clonazepam | Clonazepam | 75 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 17 |
| Lorazepam | Lorazepam | 70 | 14 |
| Spironolactone | Spironolactone | 70 | 20 |
| Simvastatin | Simvastatin | 68 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 12 |
| Allopurinol | Allopurinol | 65 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 27 |
| Glipizide Er | Glipizide | 64 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 15 |
| Ozempic | Semaglutide | 61 | 16 |
| Bupropion Xl | Bupropion Hcl | 58 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 13 |
| Carvedilol | Carvedilol | 54 | 19 |
| Donepezil Hcl | Donepezil Hcl | 54 | 18 |
| Farxiga | Dapagliflozin Propanediol | 54 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 19 |
| Cefdinir | Cefdinir | 52 | 39 |
| Chlorthalidone | Chlorthalidone | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 18 |
| Famotidine | Famotidine | 49 | 17 |
| Torsemide | Torsemide | 49 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Prednisone | Prednisone | 43 | 34 |
| Azithromycin | Azithromycin | 42 | 38 |
| Montelukast Sodium | Montelukast Sodium | 42 | 15 |
| Ondansetron Odt | Ondansetron | 42 | 24 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 12 |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 13 |
| Atenolol | Atenolol | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 31 | 14 |
| Linzess | Linaclotide | 31 | 12 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 20 |
| Finasteride | Finasteride | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Topiramate | Topiramate | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,108.45 · 54 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, OTEZLA, Ohtuvayre, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, Symbravo, TRINTELLIX, Trelstar, Tymlos, UBRELVY, VOWST, VRAYLAR, Wegovy, Xhance, ZENPEP, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error